

Resource Summary Report

Generated by [RRID](#) on Sep 11, 2026

Anti-ARID1A antibody produced in rabbit

RRID:AB_1078205

Type: Antibody

Proper Citation

Sigma-Aldrich Cat# HPA005456, RRID:AB_1078205

Antibody Information

URL: http://antibodyregistry.org/AB_1078205

Proper Citation: Sigma-Aldrich Cat# HPA005456, RRID:AB_1078205

Target Antigen: Human ARID1A

Host Organism: rabbit

Clonality: unknown

Comments: Vendor recommendations:

Antibody Name: Anti-ARID1A antibody produced in rabbit

Description: This unknown targets Human ARID1A

Target Organism: human

Antibody ID: AB_1078205

Vendor: Sigma-Aldrich

Catalog Number: HPA005456

Record Creation Time: 20231110T065112+0000

Record Last Update: 20260901T014949+0000

Ratings and Alerts

- Antibody validation available from The Human Protein Atlas - Human Protein Atlas <https://www.proteinatlas.org/search/HPA005456>

No alerts have been found for Anti-ARID1A antibody produced in rabbit.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhu X, et al. (2026) Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1632.

Loe AKH, et al. (2026) ARID1A terminates gastric regeneration to prevent cancer. *Developmental cell*, 61(7), 1471.

Simões-Sousa S, et al. (2025) ARID1A stabilizes non-homologous end joining factors at DNA breaks induced by the G4 ligand pyridostatin. *Cell reports*, 44(9), 116277.

Ngoi NYL, et al. (2025) Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(18), 3907.

Menon DU, et al. (2024) ARID1A governs the silencing of sex-linked transcription during male meiosis in the mouse. *eLife*, 12.

Barisic D, et al. (2024) ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. *Cancer cell*.

Jana S, et al. (2023) Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression. *Cancer cell*, 41(5), 853.

Kao CH, et al. (2022) Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma. *Frontiers in immunology*, 13, 1079253.

Celen C, et al. (2022) Arid1a loss potentiates pancreatic β -cell regeneration through activation of EGF signaling. *Cell reports*, 41(5), 111581.

Blümli S, et al. (2021) Acute depletion of the ARID1A subunit of SWI/SNF complexes reveals distinct pathways for activation and repression of transcription. *Cell reports*, 37(5), 109943.

Luo Q, et al. (2020) TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. *Cell reports*, 30(1), 98.

Ogiwara H, et al. (2019) Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. *Cancer cell*, 35(2), 177.

Li W, et al. (2019) A Homeostatic Arid1a-Dependent Permissive Chromatin State Licenses Hepatocyte Responsiveness to Liver-Injury-Associated YAP Signaling. *Cell stem cell*, 25(1), 54.

Ng PK, et al. (2018) Systematic Functional Annotation of Somatic Mutations in Cancer. *Cancer cell*, 33(3), 450.

Sun X, et al. (2017) Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer. *Cancer cell*, 32(5), 574.

Howat W, et al. (2014) Application of ARID1A to murine formalin-fixed paraffin embedded tissue using immunohistochemistry. *F1000Research*, 3, 244.